Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1561) 1561
pyrazinamide - therapeutic use (1294) 1294
antitubercular agents - therapeutic use (1086) 1086
science & technology (1001) 1001
isoniazid - therapeutic use (960) 960
rifampin - therapeutic use (943) 943
life sciences & biomedicine (939) 939
female (847) 847
male (835) 835
adult (728) 728
tuberculosis, pulmonary - drug therapy (656) 656
tuberculosis (639) 639
drug therapy, combination (574) 574
ethambutol - therapeutic use (543) 543
middle aged (504) 504
pyrazinamide (469) 469
infectious diseases (447) 447
biological and medical sciences (428) 428
medical sciences (424) 424
tuberculosis - drug therapy (388) 388
adolescent (329) 329
pyrazinamide - administration & dosage (311) 311
mycobacterium tuberculosis - drug effects (299) 299
treatment outcome (288) 288
aged (276) 276
rifampin - administration & dosage (275) 275
streptomycin - therapeutic use (261) 261
isoniazid - administration & dosage (259) 259
antitubercular agents - administration & dosage (253) 253
isoniazid (248) 248
pharmacology & pharmacy (241) 241
bacterial diseases (234) 234
microbiology (233) 233
pharmacology. drug treatments (231) 231
abridged index medicus (216) 216
rifampin (213) 213
animals (211) 211
human bacterial diseases (202) 202
time factors (201) 201
mycobacterium tuberculosis - isolation & purification (198) 198
antitubercular agents - adverse effects (197) 197
child (189) 189
respiratory system (184) 184
tuberculosis and atypical mycobacterial infections (180) 180
antibiotics. antiinfectious agents. antiparasitic agents (176) 176
pyrazinamide - adverse effects (173) 173
mycobacterium tuberculosis (164) 164
pyrazinamide - pharmacology (157) 157
antitubercular agents - pharmacology (150) 150
drug resistance (150) 150
drug therapy (145) 145
tuberculosis, pulmonary - microbiology (144) 144
tuberculosis, multidrug-resistant - drug therapy (143) 143
antibiotics, antitubercular - therapeutic use (141) 141
ethambutol (140) 140
general & internal medicine (138) 138
drug administration schedule (135) 135
drug resistance, microbial (134) 134
ethambutol - administration & dosage (132) 132
young adult (131) 131
ethionamide - therapeutic use (130) 130
microbial sensitivity tests (127) 127
immunology (125) 125
rifampin - adverse effects (125) 125
sputum - microbiology (124) 124
follow-up studies (122) 122
antibacterial agents (121) 121
drugs (116) 116
drug combinations (114) 114
isoniazid - adverse effects (114) 114
retrospective studies (112) 112
child, preschool (110) 110
medicine, general & internal (110) 110
antitubercular agents (108) 108
mice (108) 108
recurrence (100) 100
cycloserine - therapeutic use (99) 99
tuberculosis, pulmonary - diagnosis (95) 95
infant (94) 94
tuberculosis, pulmonary - complications (94) 94
mycobacterium tuberculosis - genetics (90) 90
risk factors (89) 89
antitubercular agents - pharmacokinetics (87) 87
pyrazinamide - pharmacokinetics (85) 85
prospective studies (84) 84
medicine (82) 82
isoniazid - pharmacology (81) 81
research article (81) 81
patients (79) 79
chemotherapy (78) 78
health aspects (76) 76
streptomycin - administration & dosage (75) 75
aged, 80 and over (74) 74
aids/hiv (74) 74
radiography (73) 73
rifampicin (72) 72
clinical trials as topic (71) 71
care and treatment (70) 70
analysis (69) 69
research (68) 68
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1590) 1590
French (82) 82
Spanish (63) 63
German (53) 53
Russian (46) 46
Portuguese (21) 21
Japanese (19) 19
Italian (17) 17
Polish (13) 13
Chinese (11) 11
Turkish (7) 7
Dutch (4) 4
Hebrew (2) 2
Hungarian (2) 2
Romanian (2) 2
Swedish (2) 2
Danish (1) 1
Korean (1) 1
Slovak (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis
by Caminero, José A, Dr and Sotgiu, Giovanni, PhD and Zumla, Alimuddin, FRCP and Migliori, Giovanni Battista, MD
The Lancet infectious diseases, ISSN 1473-3099, 2010, Volume 10, Issue 9, pp. 621 - 629
Infectious Disease | Life Sciences & Biomedicine | Infectious Diseases | Science & Technology | Biological and medical sciences | Infectious diseases | Medical sciences | Bacterial diseases | Human bacterial diseases | Tuberculosis and atypical mycobacterial infections | Extensively Drug-Resistant Tuberculosis - drug therapy | Levofloxacin | Drug Resistance, Multiple | Humans | Ofloxacin - therapeutic use | Fluoroquinolones - therapeutic use | Kanamycin - therapeutic use | Pyrazinamide - therapeutic use | Capreomycin - therapeutic use | Amikacin - therapeutic use | Antitubercular Agents - classification | Tuberculosis - drug therapy | Antitubercular Agents - standards | Isoniazid - therapeutic use | Ethambutol - therapeutic use | Antitubercular Agents - therapeutic use | Drugs | Drug resistance in microorganisms | Care and treatment | Tuberculosis | Amoxicillin | Antitubercular agents | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial
by Boeree, Martin J, PhD and Heinrich, Norbert, MD and Aarnoutse, Rob, PhD and Diacon, Andreas H, PhD and Dawson, Rodney, PhD and Rehal, Sunita, MSc and Kibiki, Gibson S, Prof and Churchyard, Gavin, Prof and Sanne, Ian, FRCP and Ntinginya, Nyanda E, MD and Minja, Lilian T, MD and Hunt, Robert D, BSc and Charalambous, Salome, PhD and Hanekom, Madeleine, PhD and Semvua, Hadija H, PhD and Mpagama, Stellah G, PhD and Manyama, Christina, MD and Mtafya, Bariki, MSc and Reither, Klaus, MD and Wallis, Robert S, Prof and Venter, Amour, NatDipMicr and Narunsky, Kim, MD and Mekota, Anka, PhD and Henne, Sonja, MSc and Colbers, Angela, PhD and van Balen, Georgette Plemper, PhD and Gillespie, Stephen H, Prof and Phillips, Patrick P J, PhD and Hoelscher, Michael, Prof and PanACEA consortium and PanACEA Consortium
The Lancet infectious diseases, ISSN 1473-3099, 2016, Volume 17, Issue 1, pp. 39 - 49
Infectious Disease | Life Sciences & Biomedicine | Infectious Diseases | Science & Technology | Drug Administration Schedule | Humans | Tanzania | Fluoroquinolones - therapeutic use | Male | Tuberculosis, Pulmonary - drug therapy | Ethylenediamines - therapeutic use | Pyrazinamide - therapeutic use | Tuberculosis, Pulmonary - diagnosis | Adamantane - therapeutic use | Adult | Female | Isoniazid - therapeutic use | Rifampin - therapeutic use | South Africa | Drug Therapy, Combination | Ethambutol - therapeutic use | Adamantane - analogs & derivatives | Antitubercular Agents - therapeutic use | Medical colleges | Tuberculosis | Pharmacy | Communicable diseases | Lung diseases | Clinical trials | Drugstores | Dosage and administration | Research institutes | Rifampin | Public health | Moxifloxacin | Analysis | Studies | Consortia | Drug dosages | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Machine learning for classifying tuberculosis drug-resistance from DNA sequencing data
by Yang, Yang and Niehaus, Katherine E and Walker, Timothy M and Iqbal, Zamin and Walker, A Sarah and Wilson, Daniel J and Peto, Tim E A and Crook, Derrick W and Smith, E Grace and Zhu, Tingting and Clifton, David A
Bioinformatics, ISSN 1367-4803, 05/2018, Volume 34, Issue 10, pp. 1666 - 1671
Statistics & Probability | Biochemistry & Molecular Biology | Physical Sciences | Computer Science, Interdisciplinary Applications | Life Sciences & Biomedicine | Technology | Biochemical Research Methods | Computer Science | Mathematics | Biotechnology & Applied Microbiology | Science & Technology | Mathematical & Computational Biology | Mycobacterium tuberculosis - classification | Ciprofloxacin - therapeutic use | Humans | Ofloxacin - therapeutic use | Tuberculosis, Multidrug-Resistant - genetics | Machine Learning | Pyrazinamide - therapeutic use | Microbial Sensitivity Tests | Moxifloxacin - therapeutic use | Streptomycin - therapeutic use | Isoniazid - therapeutic use | Rifampin - therapeutic use | Ethambutol - therapeutic use | Sequence Analysis, DNA - methods | Antitubercular Agents - therapeutic use | Mycobacterium tuberculosis - genetics | Tuberculosis, Multidrug-Resistant - drug therapy | Index Medicus | Original Papers
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Nosocomial Transmission of Extensively Drug-Resistant Tuberculosis in a Rural Hospital in South Africa
by Neel R. Gandhi and Darren Weissman and Prashini Moodley and Melissa Ramathal and Inga Elson and Barry N. Kreiswirth and Barun Mathema and Elena Shashkina and Richard Rothenberg and Anthony P. Moll and Gerald Friedland and A. Willem Sturm and N. Sarita Shah
The Journal of infectious diseases, ISSN 0022-1899, 1/2013, Volume 207, Issue 1, pp. 9 - 17
Epidemics | Ferries | BACTERIA | Tuberculosis | Disease transmission | Mycobacterium tuberculosis | HIV | Hospital admissions | Data transmission | Multidrug resistant tuberculosis | Infection control | Genotyping | Drug resistance | Transmission | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Microbiology | Science & Technology | Fundamental and applied biological sciences. Psychology | Biological and medical sciences | Infectious diseases | Medical sciences | Prevalence | Humans | Male | Cross Infection - complications | Cross Infection - transmission | Adult | Extensively Drug-Resistant Tuberculosis - microbiology | Female | Isoniazid - therapeutic use | Rifampin - therapeutic use | Retrospective Studies | Drug Therapy, Combination | Ethambutol - therapeutic use | Antitubercular Agents - therapeutic use | Cross Infection - epidemiology | Extensively Drug-Resistant Tuberculosis - complications | Mycobacterium tuberculosis - classification | HIV Infections - virology | South Africa - epidemiology | Genotype | Sequence Analysis, DNA | Mycobacterium tuberculosis - isolation & purification | Pyrazinamide - therapeutic use | Extensively Drug-Resistant Tuberculosis - epidemiology | Hospitals, Rural | Polymorphism, Restriction Fragment Length | Extensively Drug-Resistant Tuberculosis - transmission | Cross Infection - microbiology | HIV Infections - complications | Mutation | Cluster Analysis | Mycobacterium tuberculosis - genetics | Extensively drug-resistant tuberculosis | Distribution | Reports | Cross infection | Research | Nosocomial infections | Risk factors | Index Medicus | Abridged Index Medicus | Major and Brief Reports | transmission | drug resistance | tuberculosis | genotyping
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon
by Kuaban, C and Noeske, J and Rieder, H.L and Aït-Khaled, N and Abena Foe, J.L and Trébucq, A
The international journal of tuberculosis and lung disease, ISSN 1027-3719, 05/2015, Volume 19, Issue 5, pp. 517 - 524
Cameroon | Short-course | Treatment | Tuberculosis | Multidrug resistance | Respiratory System | Infectious Diseases | Life Sciences & Biomedicine | Science & Technology | Medication Adherence - statistics & numerical data | Antitubercular Agents - adverse effects | Confidence Intervals | Prospective Studies | Humans | Middle Aged | Male | Tuberculosis, Multidrug-Resistant - diagnosis | Dose-Response Relationship, Drug | Young Adult | Time Factors | Adult | Female | Isoniazid - therapeutic use | Drug Therapy, Combination | Ethambutol - therapeutic use | Odds Ratio | Antitubercular Agents - therapeutic use | Clofazimine - therapeutic use | Drug Administration Schedule | Risk Assessment | Fluoroquinolones - therapeutic use | Treatment Outcome | Kanamycin - therapeutic use | Prothionamide - therapeutic use | Pyrazinamide - therapeutic use | Drug-Related Side Effects and Adverse Reactions - epidemiology | Adolescent | Aged | Developing Countries | Cohort Studies | Tuberculosis, Multidrug-Resistant - drug therapy
Journal Article
Details down arrow
6. Full Text Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis
by Dawson, Rodney, MD and Diacon, Andreas H, MD and Everitt, Daniel, Dr and van Niekerk, Christo, MD and Donald, Peter R, MD and Burger, Divan A, MCom and Schall, Robert, PhD and Spigelman, Melvin, MD and Conradie, Almari, MPh and Eisenach, Kathleen, PhD and Venter, Amour, NatDipMicr and Ive, Prudence, FCP[SA] and Page-Shipp, Liesl, MBBCh and Variava, Ebrahim, MD and Reither, Klaus, MD and Ntinginya, Nyanda E, MD and Pym, Alexander, MD and von Groote-Bidlingmaier, Florian, MD and Mendel, Carl M, MD
The Lancet (British edition), ISSN 0140-6736, 2015, Volume 385, Issue 9979, pp. 1738 - 1747
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Sputum - microbiology | Humans | Tanzania | Fluoroquinolones - therapeutic use | Male | Treatment Outcome | Tuberculosis, Pulmonary - drug therapy | Colony Count, Microbial | Moxifloxacin | Pyrazinamide - therapeutic use | Young Adult | Nitroimidazoles - therapeutic use | Adolescent | Adult | Female | Isoniazid - therapeutic use | Rifampin - therapeutic use | South Africa | Drug Therapy, Combination | Ethambutol - therapeutic use | Antitubercular Agents - therapeutic use | Tuberculosis, Multidrug-Resistant - drug therapy | Clinical trials | Tuberculosis | International cooperation | Drug therapy | Pyrazinamide | Analysis | Pulmonary tuberculosis | Drug resistance | Efficiency | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis
by Rustomjee, R and Lienhardt, C and Kanyok, T and Davies, G.R and Levin, J and Mthiyane, T and Reddy, C and Sturm, A.W and Sirgel, F.A and Allen, J and Coleman, D.J and Fourie, B and Mitchison, D.A and Bah-Sow, O.Y and Diop, H and Fielding, K and Gninafon, M and Mitchison, D and Lienhardt, C and Odhiambo, J and Perronne, C and Portaels, F and Rustomjee, R and Ramjee, A and Master, I and Olowolagba, A and Chinappa, T and Osburne, G and Bamber, S and Pala, A.S and Pillay, L and Tembe, C and Mpangase, P and Hadebe, T and Ngcobo, C.P and Mkhize, Z and Dlamini, C.N and Gill, L and Dube, T and Saul, M and Merle, C and Suma, K.F and Gatifloxacin TB OFLOTUB Study Team and Gatifloxacin for TB (OFLOTUB) study team
The international journal of tuberculosis and lung disease, ISSN 1027-3719, 02/2008, Volume 12, Issue 2, pp. 128 - 138
FQs | Modelling | Randomised clinical trial | Pulmonary tuberculosis | Respiratory System | Infectious Diseases | Life Sciences & Biomedicine | Science & Technology | Sputum - microbiology | Aza Compounds - therapeutic use | Humans | Middle Aged | Ofloxacin - therapeutic use | Fluoroquinolones - therapeutic use | Male | Colony Count, Microbial | Pyrazinamide - therapeutic use | Anti-Bacterial Agents - therapeutic use | Adolescent | Adult | Female | Isoniazid - therapeutic use | Rifampin - therapeutic use | Aged | Quinolines - therapeutic use | Drug Therapy, Combination | Nonlinear Dynamics | Antitubercular Agents - therapeutic use
Journal Article
Details down arrow
8. Full Text Impact of Pharmacogenetic Markers of CYP2B6, Clinical Factors, and Drug-Drug Interaction on Efavirenz Concentrations in HIV/Tuberculosis-Coinfected Patients
by Weerawat Manosuthi and Chonlaphat Sukasem and Aroon Lueangniyomkul and Wiroj Mankatitham and Supeda Thongyen and Samruay Nilkamhang and Sukanya Manosuthi and Somnuek Sungkanuparph
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 02/2013, Volume 57, Issue 2, pp. 1019 - 1024
Pharmacology & Pharmacy | Life Sciences & Biomedicine | Microbiology | Science & Technology | Immunopathology | Tuberculosis and atypical mycobacterial infections | Viral diseases | Biological and medical sciences | Medical sciences | Immunodeficiencies | Infectious diseases | Bacterial diseases | Human bacterial diseases | Pharmacology. Drug treatments | Viral diseases of the lymphoid tissue and the blood. Aids | Human viral diseases | Immunodeficiencies. Immunoglobulinopathies | Antibiotics. Antiinfectious agents. Antiparasitic agents | Oxidoreductases, N-Demethylating - genetics | Reverse Transcriptase Inhibitors - blood | Humans | Middle Aged | Aryl Hydrocarbon Hydroxylases - genetics | Tuberculosis - complications | Male | Tenofovir | Young Adult | Drug Interactions | Adenine - therapeutic use | Tuberculosis - drug therapy | Lamivudine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Benzoxazines - blood | Female | Isoniazid - therapeutic use | Rifampin - therapeutic use | Anti-HIV Agents - blood | Reverse Transcriptase Inhibitors - therapeutic use | Ethambutol - therapeutic use | Antitubercular Agents - therapeutic use | HIV Infections - blood | Pharmacogenetics | Adenine - analogs & derivatives | Organophosphonates - therapeutic use | Genotype | Pyrazinamide - therapeutic use | Benzoxazines - therapeutic use | Adolescent | HIV Infections - complications | HIV Infections - drug therapy | Polymorphism, Single Nucleotide | Cytochrome P-450 CYP2B6 | Index Medicus | Body weight | Clinical Therapeutics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. TB Alliance regimen development for multidrug-resistant tuberculosis
by Murray, S and Mendel, C and Spigelman, M
The international journal of tuberculosis and lung disease, ISSN 1027-3719, 12/2016, Volume 20, Issue 12, pp. S38 - S41
Oxazolidinone | Tuberculosis | Bedaquiline | Clinical trial | Pretomanid | Moxifloxacin | Pyrazinamide | Extensively Drug-Resistant Tuberculosis - drug therapy | Linezolid - therapeutic use | Humans | Clinical Protocols | Fluoroquinolones - therapeutic use | Pyrazinamide - therapeutic use | Randomized Controlled Trials as Topic | Dose-Response Relationship, Drug | Nitroimidazoles - therapeutic use | Diarylquinolines - therapeutic use | Isoniazid - therapeutic use | Rifampin - therapeutic use | Ethambutol - therapeutic use | Research Design | Antitubercular Agents - therapeutic use | Tuberculosis, Multidrug-Resistant - drug therapy
Journal Article
Details down arrow
10. Full Text Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis
by Tasneen, Rokeya and Williams, Kathy and Amoabeng, Opokua and Minkowski, Austin and Mdluli, Khisimuzi E and Upton, Anna M and Nuermbergera, Eric L
Antimicrobial agents and chemotherapy, ISSN 0066-4804, 01/2015, Volume 59, Issue 1, pp. 129 - 135
Pharmacology & Pharmacy | Life Sciences & Biomedicine | Microbiology | Science & Technology | Clofazimine - therapeutic use | Fluoroquinolones - therapeutic use | Moxifloxacin | Random Allocation | Mycobacterium tuberculosis - drug effects | Pyrazinamide - therapeutic use | Microbial Sensitivity Tests | Animals | Nitroimidazoles - therapeutic use | Diarylquinolines - therapeutic use | Oxazines - therapeutic use | Tuberculosis - drug therapy | Female | Mice | Mice, Inbred BALB C | Drug Therapy, Combination | Oxazoles - therapeutic use | Antitubercular Agents - therapeutic use | Disease Models, Animal | Index Medicus | Experimental Therapeutics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights